Compound library / Skin, hair & topicals / Hair Loss

Spironolactone

Anti-androgen / potassium-sparing diuretic used off-label, especially in women, for androgenic alopecia and hormonal acne by blocking androgen receptors.

CategoryHair Loss
Regulatory standingNo approved product cited
Typical routeOral
Half-life~1.4 hours (active metabolites last longer, ~10-35 hours)
Common dose range25-200 mg/day (highly individualized)
Typical cycle lengthOngoing

BioHack Track models Spironolactone at a half-life of 20 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Oral tablet; no reconstitution needed.

Storage

Store at room temperature.

Cautions

Requires potassium monitoring; not appropriate for men in most cases due to anti-androgen effects, and contraindicated in pregnancy.

Track Spironolactone in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Hair Loss

What the evidence says

Evidence Check asks 10 questions about every compound. For Spironolactone it can answer 2 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.

Some Clinical EvidenceCognition

Clinical trials in humans have looked at this.

  • Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudyRandomized Controlled Trial · J Am Coll Cardiol · 2002 · PMID 12427411
Insufficient EvidenceMuscle growth

Only reviews or early work — not enough to say either way.

  • [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction]Review · Nihon Yakurigaku Zasshi · 2004 · PMID 15277727

Look up the research

These open a search of each database for Spironolactone — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Selected published studies

12 papers naming Spironolactone in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support